兴科蓉医药2025 中期报告

2025INTERIM REPORT Contents 2Corporate Information4Financial Highlights6Corporate Profile7Management Discussion and Analysis23Other Information32Independent Review Report34Interim Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income35Interim Condensed Consolidated Statement of Financial Position37Interim Condensed Consolidated Statement of Changes in Equity38Interim Condensed Consolidated Statement of Cash Flows40Notes to Interim Condensed Financial Information66Definitions Corporate Information BOARD OF DIRECTORSExecutive Directors Mr. Huang Xiangbin(Chairman)Mr. Huang Zhijian(Vice Chairman)Mr. Lei Shifeng Non-executive DirectorMs. Jing Huan Independent Non-executive Directors Mr. Bai Zhizhong(Lead Independent Non-executive Director)(appointed as Lead Independent Non-executive Director on 27 August 2025)Mr. Lau Ying KitMr. Liu WenfangMr. Wang Qing 20258 27 AUDIT COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Liu WenfangMr. Wang QingMr. Bai Zhizhong REMUNERATION COMMITTEE Mr. Wang Qing(Chairman)Mr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng NOMINATION COMMITTEE Mr. Huang Xiangbin(Chairman)Mr. Liu WenfangMr. Lau Ying KitMs. Jing Huan (appointed on 27 August 2025)Mr. Bai Zhizhong (appointed on 27 August 2025) 20258 2720258 27 INTERNAL CONTROL AND CORPORATEGOVERNANCE COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Wang QingMr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng AUTHORISED REPRESENTATIVES Mr. Huang XiangbinMs. Peng Yunlu COMPANY SECRETARY 2Sinco Pharmaceuticals Holdings LimitedInterim Report 2025 Corporate Information (Continued) REGISTERED OFFICE PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands CORPORATE HEADQUARTERS 1700E5-1805 E5-1805, Global CentreNo. 1700, North Section of Tianfu AvenueHigh-Tech Zone, ChengduSichuanPRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 1112403 Room 2403, Wing On Centre111 Connaught Road CentralHong Kong CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG BRANCH SHARE REGISTRAR Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17/F, Hopewell Centre,183 Queen’s Road EastWan ChaiHong Kong 183171712 1716 HONG KONG LEGAL ADVISER Tian Yuan Law Firm LLP AUDITOR Rongcheng (Hong Kong) CPA Limited(formerly known as CL Partners CPA Limited)Certified Public AccountantsRegistered Public Interest Entity Auditor STOCK CODE ON THE MAIN BOARD OF THE STOCKEXCHANGE OF HONG KONG LIMITED 6833 www.sinco-pharm.com COMPANY’S WEBSITEwww.sinco-pharm.com LISTING DATE10 March 2016 20163 10 Financial Highlights •Revenue of the Group decreased by 21.7% or RMB331.1 million toRMB1,195.8 million for the Reporting Period (six months ended 30June 2024: RMB1,526.9 million), among which revenue from salesof pharmaceutical products decreased by approximately RMB329.5million, while revenue from medical beauty services decreased byRMB1.6 million. •21.7%331.11,195.820246301,526.9329.51.6 •In line with the decrease in the Group’s revenue, the gross profit ofthe Group decreased by RMB42.5 million to RMB130.7 million forthe Reporting Period (six months ended 30 June 2024: RMB173.2million), while the gross profit margin decreased from 11.3% to10.9%, which was caused by the decline in the selling price due tothe intensified market competition. •42.5130.720246 30173.211.3%10.9% •During the Reporting Period, the net profit slightly increased byapproximately RMB0.5 million to RMB24.4 million (six months ended30 June 2024: RMB23.9 million). As state above, although therevenue and gross profit decreased, the overall expenses, includingselling and distribution expenses, administrative expenses andincome tax expenses, were decreased even more, so the net profithas achieved a slight increase. •0.524.420246 3023.9 •During the Reporting Period, net profit attributable to owners ofthe Company amounted to RMB24.4 million (six months ended 30June 2024: RMB23.9 million), representing an increase in net profitattributable to owners of the Company by RMB0.5 million. •24.420246 3023.90.5 •Basic and diluted earnings per share amounted to RMB0.0120 forthe Reporting Period (six months ended 30 June 2024: RMB0.0117). •0.012020246300.0117 •The Board resolved not to declare any interim dividend for theReporting Period (six months ended 30 June 2024: Nil). •20246 30 Corporate Profile As a leading MPCM service provider with extensive experience in thedistribution of pharmaceutical imports, the Group focuses on bloodproducts and, based on nationwide marketing and promotion network,provides comprehensive MPCM services for small and medium-sizedoverseas pharmaceuticals manufacturers. The Group’s products areimported from well-known overseas pha